HCW Biologics (NASDAQ:HCWB) Stock Rating Lowered by Wall Street Zen

HCW Biologics (NASDAQ:HCWB) was downgraded by analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research note issued on Saturday.

Separately, Maxim Group cut their price target on shares of HCW Biologics from $120.00 to $35.00 and set a “buy” rating on the stock in a research report on Thursday, May 29th.

HCW Biologics Stock Down 0.9%

HCW Biologics stock opened at $5.45 on Friday. The stock has a market cap of $7.84 million, a price-to-earnings ratio of -5.45 and a beta of 0.83. HCW Biologics has a 12-month low of $5.00 and a 12-month high of $100.80. The business’s 50-day simple moving average is $7.60 and its 200 day simple moving average is $12.32.

HCW Biologics (NASDAQ:HCWB) last issued its earnings results on Thursday, May 15th. The company reported ($0.05) earnings per share (EPS) for the quarter. HCW Biologics had a negative return on equity of 2,516.84% and a negative net margin of 1,067.82%.

Insider Activity at HCW Biologics

In other news, CFO Rebecca Byam bought 8,462 shares of the company’s stock in a transaction dated Thursday, May 8th. The stock was bought at an average cost of $26.00 per share, for a total transaction of $220,012.00. Following the transaction, the chief financial officer now owns 43,010 shares of the company’s stock, valued at $1,118,260. This represents a 24.49% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, SVP Lee Flowers bought 962 shares of the company’s stock in a transaction dated Thursday, May 8th. The stock was bought at an average cost of $26.00 per share, with a total value of $25,012.00. Following the acquisition, the senior vice president now directly owns 5,720 shares of the company’s stock, valued at approximately $148,720. The trade was a 20.22% increase in their position. The disclosure for this purchase can be found here. In the last 90 days, insiders have purchased 11,732 shares of company stock worth $305,032. Insiders own 42.70% of the company’s stock.

About HCW Biologics

HCW Biologics Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases in the United States. The company's lead products include HCW9218, which is in Phase 1 clinical chemo-refractory/chemo-resistant solid tumors with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as Phase 2 clinical trial with metastatic advanced stage ovarian cancer patients; and HCW9302 for autoimmune and proinflammatory diseases, such as alopecia areata diseases.